Goldman Sachs Maintains Alnylam at Buy, Cuts Target to $320
Goldman Sachs maintained its Buy rating on Alnylam Pharmaceuticals and lowered its price target to $320 from $536.
Related stories
SpaceX President Shotwell Says 2 Million Shares to Go to Trump Accounts
SpaceX President Gwynne Shotwell says 2 million shares will be gifted to children's Trump Accounts.
M impact | EQUITY | Oct 30, 2026, 09:38 PM UTC
US Elections, Earnings and Jobs Data Loom for AI-Wary Stocks
A preview flags midterm elections, earnings and jobs data as coming events for an AI-wary stock market.
M impact | EQUITY | Oct 30, 2026, 09:32 PM UTC
Digital Realty Registers Resale of Shares Issued in Teraco Stake Acquisition
Digital Realty registered the resale of shares issued in its acquisition of a stake in Teraco.
M impact | EQUITY | Oct 30, 2026, 09:29 PM UTC
S&P Global Revises Meta Outlook to Negative on Cash Flow Concerns
M impact | EQUITY | Oct 30, 2026, 09:22 PM UTC
Bank of America Reports Third-Quarter Revenue of $30B, Net Income of $6.5B
Bank of America reported third-quarter 2026 revenue of $30B, up 3.2% year over year. Net income applicable to common shareholders fell 17.2% to $6.5B, and diluted EPS declined 12.5
H impact | EQUITY | Oct 30, 2026, 09:11 PM UTC
VantageScore CEO Silvio Tavares Resigns After Five Years
VantageScore said Silvio Tavares is stepping down as president and CEO after leading the company for five years. Anthony Hutchinson was named interim president and CEO.
M impact | EQUITY | Oct 30, 2026, 09:07 PM UTC